Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02879760
Title Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Turnstone Biologics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.